NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

RegulatorypositiveNEZGLYAL®Positive

AI Analysis

Summary

NEZGLYAL® (leriglitazone) received a positive CHMP opinion for treating cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease, moving the drug closer to European approval.

Outcome Details

Positive CHMP opinion received

Importance:7/10

Sentiment:

0.80

CHMPregulatoryrare diseaseneurodegenerativeEurope

Read the original article

Published by GlobeNewswire Pharma on July 24, 2026 12:53 PM

Read Original